RESUMEN
Although thrombotic thrombocytopenic purpura (TTP) has been described in patients with systemic lupus erythematosus (SLE), the relationship between these 2 diseases is controversial. We recently treated a patient with longstanding SLE who developed TTP. The patient responded to therapy with aggressive plasmapheresis. Review of the literature revealed that TTP may occur in the setting of either active or inactive SLE. Survival in SLE associated TTP correlated with the use of plasma therapy (plasma infusion or plasmapheresis) rather than with the activity of the underlying autoimmune disease. We conclude that TTP and SLE represent distinct clinical entities that may occur together in an immunologically predisposed host. The use of plasma therapy appears to have had a significant impact on survival in these patients.
Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Púrpura Trombocitopénica Trombótica/complicaciones , Adolescente , Adulto , Niño , Femenino , Humanos , Lupus Eritematoso Sistémico/mortalidad , Lupus Eritematoso Sistémico/terapia , Masculino , Persona de Mediana Edad , Plasmaféresis , Púrpura Trombocitopénica Trombótica/mortalidad , Púrpura Trombocitopénica Trombótica/terapiaRESUMEN
The INFUSAID model #400 totally implantable drug delivery system was implanted in 17 patients for the continuous infusion of spinally administered preservative-free morphine sulfate. Sixteen patients had pain of malignant origin, and one patient had pain secondary to meningomyelocele. Over time, there was a consistent mean improvement in analgesia scores ranging from 50% to 70% of the control levels for 16 of the patients with cancer-related pain. This form of pain therapy was not successful in treating the benign pain of the patient with meningomyelocele. Overall, the patients with cancer were pleased with their pain therapy, experienced few complications, and reported improved quality of life. Continuous infusion of spinally administered narcotics using a totally implantable drug delivery system such as the INFUSAID model #400 is a safe, complication-free procedure for the control of cancer-related pain.
Asunto(s)
Morfina/administración & dosificación , Neoplasias/fisiopatología , Dolor Intratable/tratamiento farmacológico , Anciano , Atención Ambulatoria , Anestesia Epidural/instrumentación , Femenino , Humanos , Inyecciones Espinales/instrumentación , Masculino , Persona de Mediana EdadRESUMEN
Four cases of Burkitt's-like lymphoma (undifferentiated, monoclonal, B-cell tumours) in homosexual men were seen in a 9-month period in San Francisco. One tumour contained both Epstein-Barr-virus nuclear antigen (EBNA) and cytomegalovirus (CMV) antigen. Another tumour contained EBNA, and a third contained no viral antigen, but EBNA and CMV antigens were detected in the overlying epithelium. This outbreak widens the array of neoplasms affecting immunosuppressed homosexual men and provides further evidence of an oncogenic role for EBV and CMV.
Asunto(s)
Linfoma de Burkitt/epidemiología , Brotes de Enfermedades/epidemiología , Homosexualidad , Infecciones Tumorales por Virus/inmunología , Adulto , Animales , Anticuerpos Antivirales/análisis , Antígenos Virales/aislamiento & purificación , Linfocitos B , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt/inmunología , Linfoma de Burkitt/microbiología , California , Citomegalovirus/inmunología , Diagnóstico Diferencial , Herpesvirus Humano 4/inmunología , Humanos , Linfoma/epidemiología , Masculino , RiesgoRESUMEN
Following conventional surgical management, 100 patients with high risk Stage I melanoma were treated with transfer factor to reduce the incidence of disease recurrence. All patients had primary lesions invasive to Clark's level III or deeper and exceeding 1.0 mm in measured thickness. Ninety-six patients are available for analysis at 15 to 67 months (median: 30 months) after diagnosis. Nine patients have had a recurrence of disease (treatment failure), and one has died. Actuarial non-failure rate is 90%, and survival rate is 99% at five years. A nonrandomized but contemporary control group of 46 patients displaying comparable risk factors was treated with surgery alone. The non-failure rate of this group is 63%, and the survival rate is 69%, data consistent with the results of several published studies. These results suggest that transfer factor immunotherapy may be a valuable adjunct in the treatment of patients with high risk Stage I melanoma.